{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T05:16:27Z","timestamp":1767244587987,"version":"3.48.0"},"reference-count":35,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["32172496"],"award-info":[{"award-number":["32172496"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>RNA interference (RNAi) holds promise as a gene-silencing therapy for liver cancer but faces challenges related to siRNA instability, short half-life, and inefficient cellular uptake. In this study, we designed a self-assembling RNA nanoparticle targeting three oncogenes\u2014hTERT, BIRC5, and FGFR1\u2014key drivers of cancer progression. These RNA nanoparticles demonstrated enhanced stability and specificity, eliminating the need for conventional toxic delivery carriers. Functional assays revealed that the nanoparticles effectively suppressed the proliferation, migration, tumor growth and apoptosis of a Hepatocellular carcinoma cell line, Hep3B. The nanoparticles exhibited excellent safety and efficacy in xenograft model mice, without off-target toxicity. This work introduces a scalable, biocompatible RNA nanoparticle platform with multi-targeting capability, paving the way for improved RNAi-based therapeutics. Our findings offer a promising strategy for advancing personalized cancer therapies and underscore the broader potential of RNA nanotechnology in addressing complex malignancies.<\/jats:p>","DOI":"10.3390\/biom16010045","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T06:25:51Z","timestamp":1766989551000},"page":"45","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design of Anti-Tumor RNA Nanoparticles and Their Inhibitory Effect on Hep3B Liver Cancer"],"prefix":"10.3390","volume":"16","author":[{"given":"Shuyi","family":"Sun","sequence":"first","affiliation":[{"name":"Key Laboratory of Plant Secondary Metabolism and Regulation of Zhejiang Province, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Yan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Plant Secondary Metabolism and Regulation of Zhejiang Province, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China"},{"name":"Zhejiang Sci-Tech University Shaoxing Academy of Biomedicine, Shaoxing 312366, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1322-072X","authenticated-orcid":false,"given":"Zhekai","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Plant Secondary Metabolism and Regulation of Zhejiang Province, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7004-0847","authenticated-orcid":false,"given":"Weibo","family":"Jin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Plant Secondary Metabolism and Regulation of Zhejiang Province, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China"},{"name":"Zhejiang Sci-Tech University Shaoxing Academy of Biomedicine, Shaoxing 312366, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-12-401676-7.00003-6","article-title":"AEG-1\/MTDH\/LYRIC: Signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis","volume":"120","author":"Emdad","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jconrel.2022.09.040","article-title":"Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy","volume":"351","author":"Lee","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kim, M.J., Chang, H., Nam, G., Ko, Y., Kim, S.H., Roberts, T.M., and Ryu, J.H. (2021). RNAi-Based Approaches for Pancreatic Cancer Therapy. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101638"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature06179","article-title":"Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway","volume":"449","author":"John","year":"2007","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tian, Z., Liang, G., Cui, K., Liang, Y., Wang, Q., Lv, S., Cheng, X., and Zhang, L. (2021). Insight into the Prospects for RNAi Therapy of Cancer. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.644718"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"161794","DOI":"10.1155\/2014\/161794","article-title":"Lipid nanoparticles as carriers for RNAi against viral infections: Current status and future perspectives","volume":"2014","author":"Torrecilla","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/emmm.200900023","article-title":"RNAi-based therapeutics-current status, challenges and prospects","volume":"1","author":"Tiemann","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"ref_11","first-page":"3637","article-title":"Nanoparticle-based delivery of small interfering RNA: Challenges for cancer therapy","volume":"7","author":"Miele","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature06765","article-title":"Sequence- and target-independent angiogenesis suppression by siRNA via TLR3","volume":"452","author":"Kleinman","year":"2008","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tibtech.2010.07.009","article-title":"RNAi and small interfering RNAs in human disease therapeutic applications","volume":"28","author":"Lares","year":"2010","journal-title":"Trends Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.addr.2010.03.008","article-title":"Engineering RNA for targeted siRNA delivery and medical application","volume":"62","author":"Guo","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1242\/jcs.066399","article-title":"Breaking down the barriers: siRNA delivery and endosome escape","volume":"123","author":"Dominska","year":"2010","journal-title":"J. Cell Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/IJN.S399318","article-title":"Nanoparticles Mediated circROBO1 Silencing to Inhibit Hepatocellular Carcinoma Progression by Modulating miR-130a-5p\/CCNT2 Axis","volume":"18","author":"Meng","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Piscatelli, J.A., Ban, J., Lucas, A.T., and Zamboni, W.C. (2021). Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010114"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1097\/CM9.0000000000003092","article-title":"Colon cancer-associated transcript 1 (CCAT1): A potential novel target in cancer therapy","volume":"137","author":"Ma","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1039\/C5BM00002E","article-title":"Trigger responsive polymeric nanocarriers for cancer therapy","volume":"3","author":"Kaur","year":"2015","journal-title":"Biomater. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1582","DOI":"10.1002\/wnan.1582","article-title":"Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation","volume":"12","author":"Guo","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/nat.2012.0350","article-title":"Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology","volume":"22","author":"Guo","year":"2012","journal-title":"Nucleic Acid. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/jcb.27089","article-title":"Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells","volume":"120","author":"Abbaszadeh","year":"2019","journal-title":"J. Cell Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/onc.2015.264","article-title":"BIRC5\/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma","volume":"35","author":"Hagenbuchner","year":"2016","journal-title":"Oncogene"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","unstructured":"(2023). Laboratory Animal\u2014Environment and Housing Facilities (Standard No. GB 14925-2023). Available online: https:\/\/www.chinesestandard.net\/PDF\/English.aspx\/GB14925-2023."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/00236772221097472","article-title":"A review of methods used to kill laboratory rodents: Issues and opportunities","volume":"56","author":"Clarkson","year":"2022","journal-title":"Lab. Anim."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1970121","DOI":"10.1002\/adfm.201970121","article-title":"Lung-Targeted Rnai Therapeutics: Lung-Endothelium-Targeted Nanoparticles Based on a pH-Sensitive Lipid and the GALA Peptide Enable Robust Gene Silencing and the Regression of Metastatic Lung Cancer","volume":"29","author":"Khalil","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"965","DOI":"10.7150\/thno.102964","article-title":"RNA nanotherapeutics for hepatocellular carcinoma treatment","volume":"15","author":"Yuan","year":"2025","journal-title":"Theranostics"},{"key":"ref_31","unstructured":"Rav\u00e0, M. (2015). Functional Dissection of ST18 in Liver Cancer. [Doctoral Thesis, Universit\u00e0 degli Studi di Milano]."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","article-title":"Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: Mechanistic insights, clinical efficacy, and future perspectives","volume":"17","author":"Chen","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0031-6865(97)00019-8","article-title":"Physicochemical properties and in vitro toxicity of cationic liposome cDNA complexes","volume":"72","author":"Schreier","year":"1997","journal-title":"Pharm. Acta Helv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15621","DOI":"10.1074\/jbc.273.25.15621","article-title":"Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides","volume":"273","author":"Meyer","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1021\/acs.jmedchem.2c00024","article-title":"The Progress and Promise of RNA Medicine\u2500An Arsenal of Targeted Treatments","volume":"65","author":"Sasso","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/1\/45\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T05:12:31Z","timestamp":1767244351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/1\/45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["biom16010045"],"URL":"https:\/\/doi.org\/10.3390\/biom16010045","relation":{},"ISSN":["2218-273X"],"issn-type":[{"type":"electronic","value":"2218-273X"}],"subject":[],"published":{"date-parts":[[2025,12,26]]}}}